全文获取类型
收费全文 | 13633篇 |
免费 | 1039篇 |
国内免费 | 338篇 |
专业分类
耳鼻咽喉 | 657篇 |
儿科学 | 556篇 |
妇产科学 | 62篇 |
基础医学 | 1506篇 |
口腔科学 | 417篇 |
临床医学 | 1902篇 |
内科学 | 2244篇 |
皮肤病学 | 17篇 |
神经病学 | 356篇 |
特种医学 | 342篇 |
外国民族医学 | 2篇 |
外科学 | 2537篇 |
综合类 | 2186篇 |
现状与发展 | 1篇 |
预防医学 | 549篇 |
眼科学 | 28篇 |
药学 | 1143篇 |
7篇 | |
中国医学 | 327篇 |
肿瘤学 | 171篇 |
出版年
2024年 | 10篇 |
2023年 | 264篇 |
2022年 | 360篇 |
2021年 | 519篇 |
2020年 | 614篇 |
2019年 | 553篇 |
2018年 | 590篇 |
2017年 | 535篇 |
2016年 | 558篇 |
2015年 | 545篇 |
2014年 | 1059篇 |
2013年 | 1052篇 |
2012年 | 850篇 |
2011年 | 961篇 |
2010年 | 745篇 |
2009年 | 721篇 |
2008年 | 718篇 |
2007年 | 660篇 |
2006年 | 553篇 |
2005年 | 462篇 |
2004年 | 407篇 |
2003年 | 299篇 |
2002年 | 280篇 |
2001年 | 245篇 |
2000年 | 184篇 |
1999年 | 174篇 |
1998年 | 129篇 |
1997年 | 130篇 |
1996年 | 106篇 |
1995年 | 102篇 |
1994年 | 88篇 |
1993年 | 79篇 |
1992年 | 62篇 |
1991年 | 57篇 |
1990年 | 34篇 |
1989年 | 37篇 |
1988年 | 30篇 |
1987年 | 27篇 |
1986年 | 25篇 |
1985年 | 50篇 |
1984年 | 21篇 |
1983年 | 21篇 |
1982年 | 26篇 |
1981年 | 16篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 9篇 |
1976年 | 4篇 |
1975年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的 分析双水平气道正压双水平气道正压通气(bi-level positive airway pressure,BiPAP)对阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea hypopnea syndrome,OSAHS)患者血管内皮功能及预后的影响。
方法 将100例OSAHS患者纳入研究,随机分为观察及对照组,各50例。观察组行BiPAP
,对照组行常规治疗,比较两组多导睡眠监测(polysomnography,PSG)检查指标(低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数、90%以下血氧饱和度时间)、心肺功能[脑钠肽(brainnatriureticpeptide,BNP)、右心室Tei指数、左心室Tei指数、一秒用力呼气容积占用力肺活量的百分比(forced expiratory volume in one second/forced vital capacity,FEV1/FVC)、一秒用力呼气容积占预计值的百分比(FEV1占预计值%)]、血管内皮功能[内皮素1(endothelin-1,ET-1)、一氧化氮(nitric oxide,NO)、凝血酶Ⅲ(antithrombin Ⅲ,AT-Ⅲ)]及生活质量。
结果 观察组低通气指数、呼吸暂停指数、呼吸暂停及低通气时间、90%以下血氧饱和度次数及时间指标均显著低于对照组(P<0.05)。观察组治疗后BNP以及Tei指数显著低于治疗前及对照组治疗后,FEV1/FVC、FEV1占预计值%显著高于治疗前及对照组治疗后(P<0.05)。观察组治疗后ET-1、AT-Ⅲ低于治疗前及对照组治疗后,NO高于治疗前及对照组治疗后(P<0.05)。观察组治疗后生活质量各项目评分高于对照组(P<0.05)。
结论 BiPAP治疗能够改善OSAHS患者的预后情况及血管内皮功能,效果确切。 相似文献
3.
4.
5.
6.
7.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
8.
目的分析重症肺炎并呼吸衰竭患儿接受早期持续气道正压通气(CPAP)治疗对血气指标及预后的影响。方法选取2019年2月至2020年6月本院收治的110例重症肺炎并呼吸衰竭患儿,按照组间基本资料具有可比性的原则分为对照组与实验组,各55例。对照组接受常规方案治疗,实验组接受早期持续CPAP治疗,比较两组血气指标改善情况以及患儿预后。结果治疗后,两组PaO2、PaCO2、SaO2均显著改善,且实验组改善程度明显优于对照组(P<0.05)。实验组临床病死率明显低于对照组(P<0.05)。两组并发症发生率比较差异无统计学意义。结论采用早期持续CPAP治疗重症肺炎并呼吸衰竭患儿效果显著,能明显改善血气指标和预后,具有临床推广价值。 相似文献
9.
10.
《Actas urologicas espa?olas》2019,43(7):371-377
ObjectiveTo report the clinical evolution and the urodynamic behaviour of several lower tract urinary symptoms in patients with obstructive sleep apnea syndrome before and after the treatment with continuous positive airway pressure (CPAP) devices.MethodsA prospective study was performed; patients with recent diagnosis of sleep apnea confirmed by nocturnal sleep polygraphy and absence of medical urological past history. In order to discard important lower urinary tract conditions, urological examinations were previously performed. Urinary symptoms were evaluated using the IPSS and OAB-V8 validated questionnaires, three-day Bladder Diary and invasive urodynamic examinations with a gap of one year before and one year after using the CPAP.Results84 urodynamic studies were carried out in 43 patients. The IPSS score decreased by 3.58 points. The OAB-V8 score decreased by 2.87 points. Nocturia episodes decreased to one per night. The percentage of patients with nocturnal polyuria went down to 26%. The bladder compliance significantly increased (97.39 vs 200.40 ml/cm H2O). The presence of detrusor overactivity decreased from 11 (before CPAP) to 5 patients (after CPAP).ConclusionThe proper treatment with CPAP showed a statistical and clinical improvement of several LUTS with limited urodynamic modifications. 相似文献